According to a new report by Polaris Market Research, the global gene delivery technologies market was valued at USD 6.05 billion in 2025 and is projected to reach USD 15.93 billion by 2034, expanding at a CAGR of 11.1% over the 2026–2034 forecast period. Growth is underpinned by rising demand for gene therapy, a growing global prevalence of genetic disorders and chronic diseases, and accelerating innovation in non-viral vectors, CRISPR systems, and AI-based delivery platforms.

What Is Driving Gene Delivery Technologies Market Growth?

Demand is climbing as the rising global burden of genetic disorders and chronic diseases converges with growing clinical and commercial investment in targeted therapeutics. The World Health Organization attributes 43 million deaths in 2021, or 75% of the global total, to non-communicable diseases, while the U.S. National Organization for Rare Disorders estimates that 25–30 million Americans live with a rare disease. Manufacturers and research institutes are prioritizing safer, more precise viral and non-viral vectors, pushing gene delivery adoption across infectious disease, oncology, and CNS applications. Polaris analysts note that the biological mode's dominance in viral vector-based delivery positions the segment for sustained growth through 2034, with infectious diseases already the largest revenue contributor and oncology emerging as the fastest-growing application as cancer incidence climbs.

Key Trends Shaping the Gene Delivery Technologies Industry

AI- and CRISPR-Enabled Precision Delivery Platforms

AI-assisted delivery platforms and CRISPR-based therapies are improving safety, target specificity, and therapeutic effectiveness. This technology advancement is streamlining manufacturing as well as treatment design — in August 2025, HORIBA and Fujifilm jointly developed a gene delivery system aimed at improving productivity in gene therapy manufacturing.

Rising Investment and Strategic Partnerships

Capital is flowing into next-generation delivery mechanisms: in August 2025, Merck KGaA partnered with Skyhawk Therapeutics in a deal worth up to USD 2 billion to advance RNA-targeting gene delivery technologies for neurological diseases, reflecting a strengthening market outlook for precision RNA platforms. In May 2025, GenScript launched a GMP-like mRNA manufacturing platform to accelerate early-stage drug development and gene delivery research.

Expanding Clinical and Manufacturing Infrastructure

Investment in dedicated cell and gene therapy infrastructure is broadening the competitive landscape. In April 2025, Thermo Fisher Scientific launched its first U.S. cell and gene therapy collaboration center to advance process development and manufacturing for gene delivery and therapeutic applications, supporting the industry's shift toward scaled, GMP-grade production.

Market Segmentation: Breaking Down the Gene Delivery Technologies Market

Polaris segments the gene delivery technologies market by mode, method, application, end user, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Mode

The biological segment dominated the market in 2024, driven by high adoption of viral vector-based gene delivery systems in treating rare genetic disorders and chronic diseases. The chemical segment is expected to register the highest CAGR through 2034 as innovations in non-viral chemical vectors deliver better safety profiles and efficacy for research and clinical applications.

By Method

The ex vivo segment led the market in 2024 owing to extensive application in modifying patient-derived cells prior to transplantation and its utility in personalized gene therapy. The in vivo segment is projected to post the highest CAGR as demand grows for direct gene delivery to patients, supported by ongoing advances in viral and non-viral vectors.

By Application

Infectious diseases represented the dominant application in 2024, driven by the adoption of gene-based vaccines and therapies. Oncology is expected to grow at the fastest CAGR through 2034 — the WHO projects global cancer incidence will rise from 20 million cases in 2022 to over 35 million by 2050 — fueling demand for gene therapy in cancer treatment.

By End User

Academic and research institutes dominated the market in 2024, supported by extensive laboratory and experimental use and continued funding for genetic research. Pharmaceutical and biotechnology companies are projected to grow at the fastest CAGR as gene therapy development pipelines and clinical trial activity expand alongside strategic partnerships that accelerate commercialization.

Regional Outlook: Where Is the Gene Delivery Technologies Market Growing Fastest?

North America led the market in 2025, supported by high adoption of advanced viral and non-viral delivery systems, well-established healthcare infrastructure, and strong R&D investment, with the U.S. as the region's dominant market on the back of extensive clinical trial activity and supportive reimbursement policies. Asia Pacific is the fastest-growing region, driven by rising awareness of gene therapies and an expanding patient population for genetic disorders — India's Nizam's Institute of Medical Sciences reported a 418% increase in genetic disorder cases over the past decade, treating 12,042 patients for rare genetic ailments in 2024 alone. China led APAC growth on the strength of government programs favoring gene therapy development and partnerships between regional biotech firms and international players.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/gene-delivery-technologies-market 

Competitive Landscape: Leading Gene Delivery Technologies Companies

Key players profiled in the report include Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Revvity, Inc., QIAGEN N.V., GenScript Biotech Corp., Takara Bio USA, Inc., Promega Corporation, Bio-Techne Corporation, Lonza Group AG, Oxford Biomedica PLC, Sartorius AG, and MaxCyte, Inc., who are focusing on AI implementation, CRISPR-based treatment platforms, and research collaborations to strengthen market position across the biological and infectious disease segments outlined above. Recent moves include Merck KGaA's Skyhawk Therapeutics partnership and Thermo Fisher Scientific's new U.S. cell and gene therapy collaboration center.

Why It Matters for Buyers Evaluating Gene Delivery Market Entry

For stakeholders researching the gene delivery technologies market forecast, this report benchmarks market share, segment-level pricing, and forecast data — by mode, method, application, end user, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing vector and platform suppliers, investors sizing entry points, and strategy teams tracking CRISPR and non-viral delivery as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Over-The-Top Video Market

B2B E-commerce in Agriculture Market

Anastomosis Devices Market

Metal Li-based Battery Casing Market

Multi-Deck Refrigerated Display Cases Market

Multi-Deck Refrigerated Display Cases Market

Lifting Hooks Market

Attention Deficit Hyperactivity Disorder Market

Release Liners Market